MCID: MLG068
MIFTS: 47

Malignant Glioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Glioma

MalaCards integrated aliases for Malignant Glioma:

Name: Malignant Glioma 38 12 55 15 73
Malignant Neuroglial Tumor 12
Glioma, Malignant 12
Glial Cell Tumor 12
Neuroglial Tumor 12
Glioma 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3070
MeSH 44 D005910
NCIt 50 C3059 C4822
SNOMED-CT 68 74532006

Summaries for Malignant Glioma

Disease Ontology : 12 A cell type cancer that has material basis in glial cells and is located in brain or located in spine.

MalaCards based summary : Malignant Glioma, also known as malignant neuroglial tumor, is related to astrocytoma and glioma. An important gene associated with Malignant Glioma is FOXD3-AS1 (FOXD3 Antisense RNA 1). The drugs Gliadel Wafer and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone.

Related Diseases for Malignant Glioma

Diseases in the Glioma family:

Malignant Glioma Benign Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 astrocytoma 32.5 CCDC26 HOTAIR HOXA-AS3
2 glioma 32.0 HOTAIR HOTTIP NEAT1 PVT1 SPRY4-IT1 TP53COR1
3 osteogenic sarcoma 29.9 HOTAIR HOTTIP NEAT1 PVT1
4 b-cell lymphomas 29.8 HOTAIR PVT1 TP53COR1
5 hepatocellular carcinoma 29.8 HOTAIR HOTTIP HOXA-AS2 NEAT1 PVT1 SPRY4-IT1
6 melanoma 29.7 HOTAIR HOXA-AS2 PVT1 SPRY4-IT1
7 pancreatic cancer 29.7 CCDC26 HOTAIR HOTTIP NEAT1 PVT1 SPRY4-IT1
8 thyroid cancer, nonmedullary, 1 29.7 HOTAIR HOTTIP NEAT1 PVT1
9 gastric cancer 29.5 HOTAIR HOTTIP HOXA-AS2 NEAT1 PRNCR1 PVT1
10 breast cancer 29.5 CCDC26 HOTAIR HOTTIP HOXA-AS2 NEAT1 PVT1
11 prostate cancer 29.3 HOTAIR HOTTIP NEAT1 PCGEM1 PRNCR1 PVT1
12 diffuse intrinsic pontine glioma 12.4
13 glioma susceptibility 2 12.4
14 childhood brain stem glioma 12.4
15 glioma susceptibility 3 12.3
16 glioma susceptibility 9 12.3
17 third ventricle chordoid glioma 12.2
18 chordoid glioma 12.2
19 subependymal glioma 12.2
20 spinal cord glioma 12.1
21 childhood optic nerve glioma 12.1
22 angiocentric glioma 12.1
23 glioma susceptibility 4 12.0
24 glioma susceptibility 6 12.0
25 glioma susceptibility 8 12.0
26 adult brainstem mixed glioma 12.0
27 glioma susceptibility 5 12.0
28 glioma susceptibility 7 12.0
29 benign glioma 12.0
30 visual pathway and hypothalamic glioma, childhood 11.9
31 limbic encephalitis with lgi1 antibodies 11.6
32 nasal glial heterotopia 11.4
33 oligodendroglioma 11.3
34 neurofibromatosis, type iv, of riccardi 11.3
35 retinoblastoma 11.3
36 gliosarcoma 11.3
37 oligoastrocytoma 11.3
38 pituicytoma 11.3
39 subependymoma 11.3
40 encephalocraniocutaneous lipomatosis 11.3
41 legius syndrome 11.2
42 brain stem glioma 11.2
43 adult brain stem glioma 11.2
44 mixed glioma 11.2
45 mismatch repair cancer syndrome 11.1
46 meningioma, familial 11.1
47 malignant ependymoma 11.1
48 neurofibromatosis-noonan syndrome 10.9
49 brain glioblastoma multiforme 10.9
50 brain oligodendroglioma 10.9

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma

Symptoms & Phenotypes for Malignant Glioma

Drugs & Therapeutics for Malignant Glioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
2
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
3
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 1195765-45-7 44462760 44516822
4
Trametinib Approved Phase 4,Phase 2,Phase 1 871700-17-3 11707110
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
7 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
11
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
12
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
14
Ifosfamide Approved Phase 3 3778-73-2 3690
15
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
16
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
17
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
18
Levoleucovorin Approved, Investigational Phase 3,Phase 1 68538-85-2
19
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
20
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
21
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
22
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
23
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
24
Procarbazine Approved, Investigational Phase 3,Phase 2,Not Applicable 671-16-9 4915
25
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
26
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
27
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
28
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
29
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
30
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
31
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
32
Dalteparin Approved Phase 3,Not Applicable 9005-49-6
33
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
34
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
35
Modafinil Approved, Investigational Phase 3,Phase 2 68693-11-8 4236
36
Armodafinil Approved, Investigational Phase 3,Phase 2 112111-43-0
37
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
38
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
39
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
40
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
41 tannic acid Approved Phase 3,Phase 2
42
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
44
Vitamin C Approved, Nutraceutical Phase 3,Phase 1 50-81-7 5785 54670067
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
46
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
47
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
48 Micronutrients Phase 3,Phase 1,Phase 2
49 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Photosensitizing Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 702)
# Name Status NCT ID Phase Drugs
1 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
2 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
3 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
4 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
5 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
6 Fluorescence-guided Surgery for Low- and High-grade Gliomas Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
7 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
8 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
9 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
10 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
11 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
12 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
13 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
14 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
15 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
16 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
17 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
18 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
19 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
20 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
21 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
22 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
23 Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Recruiting NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
24 Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
25 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
26 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
27 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
28 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
29 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Active, not recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
30 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
31 XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
32 Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT01144988 Phase 2 Bevacizumab / Irinotecan
33 Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Unknown status NCT01670890 Phase 2 TMZ;TMZ plus CDDP
34 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
35 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma Unknown status NCT00283543 Phase 2 Gliadel Wafer;Temozolomide
36 Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma Unknown status NCT01235845 Phase 1, Phase 2
37 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
38 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
39 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
40 A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660283 Phase 2 Temozolomide
41 A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660621 Phase 2 Temozolomide and Bevacizumab
42 Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma Unknown status NCT02481960 Phase 1, Phase 2
43 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
44 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status NCT02238496 Phase 2 Perifosine;Temsirolimus
45 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
46 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
47 Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) Unknown status NCT02772094 Phase 2
48 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00100802 Phase 2 lomustine;temozolomide
49 CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Unknown status NCT02617134 Phase 1, Phase 2
50 Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00906516 Phase 2 Neuradiab in combination with Bevacizumab (Avastin)

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Cochrane evidence based reviews: glioma

Genetic Tests for Malignant Glioma

Anatomical Context for Malignant Glioma

MalaCards organs/tissues related to Malignant Glioma:

41
Brain, T Cells, Bone, Endothelial, Spinal Cord, Testes, Kidney

Publications for Malignant Glioma

Articles related to Malignant Glioma:

(show top 50) (show all 1239)
# Title Authors Year
1
Delta-24-RGD Adenoviral Therapy Directs Oncolytic and Immune-Mediated Anti-Tumor Effects in Recurrent Malignant Glioma Patients. ( 30395338 )
2019
2
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
3
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. ( 29666296 )
2018
4
Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy. ( 29632751 )
2018
5
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. ( 29571074 )
2018
6
Sinomenine Induces G1-Phase Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells Via Downregulation of Sirtuin 1 and Induction of p53 Acetylation. ( 29756546 )
2018
7
Hyperbaric oxygen inhibits production of CD3+ T cells in the thymus and facilitates malignant glioma cell growth. ( 29785863 )
2018
8
The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. ( 29644006 )
2018
9
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
10
Immunotherapies for malignant glioma. ( 29242608 )
2018
11
Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma. ( 29343959 )
2018
12
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. ( 29404979 )
2018
13
Combination therapy of intravenously injected microglia and radiotherapy prolongs survival in a rat model of spontaneous malignant glioma. ( 29928947 )
2018
14
Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma. ( 29689474 )
2018
15
5-ALA in the management of malignant glioma. ( 29737540 )
2018
16
Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats. ( 29658349 )
2018
17
Par-4-dependent p53 up-regulation plays a critical role in thymoquinone-induced cellular senescence in human malignant glioma cells. ( 29656006 )
2018
18
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. ( 29208287 )
2018
19
Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis. ( 29310118 )
2018
20
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. ( 29712687 )
2018
21
B<i>m</i>K CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells<i>in vitro</i>through blocking the AKT signaling pathway. ( 29434848 )
2018
22
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. ( 29391393 )
2018
23
Microfluidics in Malignant Glioma Research and Precision Medicine. ( 29780878 )
2018
24
&amp;quot;Simple Methods to Derive Primary Malignant Glioma Cell Lines and Assay of Cellular Damage for Preclinical Studies&amp;quot;. ( 29405781 )
2018
25
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. ( 29703821 )
2018
26
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. ( 29133513 )
2018
27
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma. ( 29780071 )
2018
28
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. ( 29432077 )
2018
29
Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. ( 29251333 )
2018
30
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line. ( 29747444 )
2018
31
LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma. ( 29723732 )
2018
32
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( 29780148 )
2018
33
Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. ( 30498094 )
2018
34
Effects of nuclear factor I phosphorylation on calpastatin (CAST) gene variant expression and subcellular distribution in malignant glioma cells. ( 30504225 )
2018
35
Sonodynamic Therapy for Malignant Glioma Using 220-kHz Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound and 5-Aminolevulinic acid. ( 30522817 )
2018
36
Magmas inhibition as a potential treatment strategy in malignant glioma. ( 30414099 )
2018
37
Nursing Guide to Management of Major Symptoms in Patients with Malignant Glioma. ( 30424920 )
2018
38
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. ( 30430205 )
2018
39
Sodium fluorescein guided resection of malignant glioma. ( 30323373 )
2018
40
Retraction notice to "Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines" [Surgical Neurology 68 (2007) 613-614]. ( 30347583 )
2018
41
Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. ( 30366937 )
2018
42
Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. ( 30367915 )
2018
43
Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage. ( 30370358 )
2018
44
Drug Repurposing of Metabolic Agents in Malignant Glioma. ( 30223473 )
2018
45
TGF-β/Smads Signaling Affects Radiation Response and Prolongs Survival by Regulating DNA Repair Genes in Malignant Glioma. ( 30230914 )
2018
46
miR-126 Suppresses Invasion and Migration of Malignant Glioma by Targeting Mature T Cell Proliferation 1 (MTCP1). ( 30233082 )
2018
47
11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. ( 30239314 )
2018
48
Novel Chemically Synthesized, Alpha-Mangostin-Loaded Nano-Particles, Enhanced Cell Death Through Multiple Pathways Against Malignant Glioma. ( 30165924 )
2018
49
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway. ( 30217261 )
2018
50
PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. ( 30217967 )
2018

Variations for Malignant Glioma

Copy number variations for Malignant Glioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for Malignant Glioma

Search GEO for disease gene expression data for Malignant Glioma.

Pathways for Malignant Glioma

GO Terms for Malignant Glioma

Sources for Malignant Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....